AndroGel® + Placebo
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Hypogonadism
Conditions
Hypogonadism, Cardiovascular Diseases
Trial Timeline
May 3, 2018 → Jan 19, 2023
NCT ID
NCT03518034About AndroGel® + Placebo
AndroGel® + Placebo is a approved stage product being developed by AbbVie for Hypogonadism. The current trial status is completed. This product is registered under clinical trial identifier NCT03518034. Target conditions include Hypogonadism, Cardiovascular Diseases.
What happened to similar drugs?
5 of 18 similar drugs in Hypogonadism were approved
Approved (5) Terminated (3) Active (12)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03518034 | Approved | Completed |
Competing Products
20 competing products in Hypogonadism